Jpmorgan Chase & CO Purple Biotech Ltd. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 859 shares of PPBT stock, worth $317. This represents 0.0% of its overall portfolio holdings.
Number of Shares
859Holding current value
$317% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding PPBT
# of Institutions
23Shares Held
2.64MCall Options Held
6.6KPut Options Held
0-
Armistice Capital, LLC New York, NY2.12MShares$782,5500.02% of portfolio
-
Kingswood Wealth Advisors, LLC San Diego, CA186KShares$68,8570.01% of portfolio
-
Morgan Stanley New York, NY137KShares$50,5450.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il58KShares$21,4680.0% of portfolio
-
Xtx Topco LTD London, X029.1KShares$10,7660.0% of portfolio
About PURPLE BIOTECH LTD.
- Ticker PPBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,303,300
- Market Cap $6.77M
- Description
- Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...